ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 560

There Is No Further Gain from Calculating Disease Activity Score in 28 Joints with High Sensitivity Assays of C-Reactive Protein Because of High Intraindividual Variability of CRP: A Cross Sectional Study and Theoretical Consideration

Inger Marie J. Hansen1,2,3, Rikke Asmussen4, Steen Antonsen5 and Amir Emamifar6, 1Department of Reumatology, OUH, Svendborg Hospital, Svendborg, Denmark, 2University of Southern Denmark, 5000 Odense, Denmark, 3DANBIO, Glostrup, Denmark, 4Dep. of Rheumatology, OUH, Svendborg Hospital, Svendborg, Denmark, 5Biochemestry, OUH, Svendborg Hospital, 5700 Svendborg, Denmark, 6Rheumatology, OUH, Svendborg Hospital, 5700 Svendborg, Denmark

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: C-reactive protein (CRP), Disease Activity and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Sunday, November 13, 2016

Session Title: Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The threshold for reporting of C-reactive protein (CRP) differs from laboratory to laboratory. Moreover, CRP values are affected by the intra individual biological variability.[1] With respect to disease activity score in 28 joints (DAS28) and Rheumatoid Arthritis (RA), precise threshold for reporting CRP is important due to the direct effects of CRP on calculating DAS28, patient classification and subsequent treatment decisions[2]

Methods: This study consists of two sections: a theoretical consideration discussing the performance of CRP in calculating DAS28 with regard to the biological variation and reporting limit for CRP and a cross sectional study of  all RA patients from our department (n=876) applying our theoretical results. In the second section, we calculate DAS28 twice with actual CRP and CRP=9, the latter to elucidate the positive consequences of changing the lower reporting limit of CRP from <10mg/L to <3mg/L

Results: Theoretical considerations: lower reporting limit of <10mg/L leads to inaccurate patient classification in a great number of patients both because of biological variation, as well as the larger spectrum of numbers (0-9). In addition, reducing lower reporting limit for CRP to minimum<3mg/L results in optimizing patient classification (Figure 1). The logarithmic transformation of CRP in DAS28 formula has an important role Cross sectional study: 769 patients fulfilled the ACR criteria for RA were included, 107 excluded due to missing parameter used for DAS28 calculations. There was a statistically significant difference between patients´ DAS28 and new calculated DAS28 with CRP=9 (p<0.001). A total of 109 patients had a disease activity deviation (remission to low: 66, low to moderate: 39, moderate to high: 4)

Conclusion: Respecting DAS28 calculation, lower reporting limit for CRP<3 mg/L is acceptable and should be taken into consideration. A lower reporting limit for CRP<10 mg/l is too high. It is particularly relevant if treatment decisions are solely made on the basis of DAS28. Furthermore, we conclude that DAS28 in studies where the reporting limit of CRP is unknown are incomparable References:1.Macy EM, et al. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem. 1997;43:52-8 2.Asmussen R, Antonsen S, Hansen IMJ. The influence of variation in C-reactive protein values on the DAS28 score. Ann Rheum Dis 2013;72:844

Figure 1: Dependency of Disease Activity Score in 28 joints to CRP (theoretical consideration). Tender joint: 3, Swollen joint: 1, patient global assessment: 34 and CRP ranges from 0 to 40.  CRP: C-reactive protein.  CV-Within: Intra-individual biologic variability


Disclosure: I. M. J. Hansen, None; R. Asmussen, None; S. Antonsen, None; A. Emamifar, None.

To cite this abstract in AMA style:

Hansen IMJ, Asmussen R, Antonsen S, Emamifar A. There Is No Further Gain from Calculating Disease Activity Score in 28 Joints with High Sensitivity Assays of C-Reactive Protein Because of High Intraindividual Variability of CRP: A Cross Sectional Study and Theoretical Consideration [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/there-is-no-further-gain-from-calculating-disease-activity-score-in-28-joints-with-high-sensitivity-assays-of-c-reactive-protein-because-of-high-intraindividual-variability-of-crp-a-cross-sectional-s/. Accessed January 16, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/there-is-no-further-gain-from-calculating-disease-activity-score-in-28-joints-with-high-sensitivity-assays-of-c-reactive-protein-because-of-high-intraindividual-variability-of-crp-a-cross-sectional-s/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.